Arbutus Biopharma Corporation (ABUS)
NASDAQ: ABUS · Real-Time Price · USD
4.710
-0.010 (-0.21%)
At close: Mar 10, 2026, 4:00 PM EDT
4.800
+0.090 (1.91%)
After-hours: Mar 10, 2026, 7:58 PM EDT
Arbutus Biopharma Employees
Arbutus Biopharma had 44 employees as of December 31, 2024. The number of employees decreased by 29 or -39.73% compared to the previous year.
Employees
44
Change (1Y)
-29
Growth (1Y)
-39.73%
Revenue / Employee
$331,955
Profits / Employee
-$960,841
Market Cap
905.85M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 44 | -29 | -39.73% | 44 | 0 |
| Dec 31, 2023 | 73 | -25 | -25.51% | 73 | 0 |
| Dec 31, 2022 | 98 | 11 | 12.64% | 96 | 2 |
| Dec 31, 2021 | 87 | 9 | 11.54% | 85 | 2 |
| Dec 31, 2020 | 78 | -2 | -2.50% | 76 | 2 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Fortrea Holdings | 14,300 |
| Valneva SE | 700 |
| Maravai LifeSciences Holdings | 435 |
| Phathom Pharmaceuticals | 371 |
| KalVista Pharmaceuticals | 270 |
| Xencor | 260 |
| Sana Biotechnology | 194 |
| ARS Pharmaceuticals | 167 |
ABUS News
- 7 days ago - Moderna to Pay $950 Million to Settle Patent Cases From Arbutus, Genevant - WSJ
- 7 days ago - Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute - Reuters
- 7 days ago - Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna - GlobeNewsWire
- 7 days ago - Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna - GlobeNewsWire
- 7 days ago - Moderna Resolves Global Patent Litigation with Arbutus/Genevant - Accesswire
- 5 weeks ago - Arbutus Biopharma: LNP Litigation And Imdusiran Drive Near-Term Catalysts - Seeking Alpha
- 4 months ago - Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 months ago - Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025 - GlobeNewsWire